Canaccord Genuity Group Issues Positive Forecast for Ascendis Pharma A/S (NASDAQ:ASND) Stock Price

Ascendis Pharma A/S (NASDAQ:ASND) had its price target upped by analysts at Canaccord Genuity Group from $268.00 to $274.00 in a research note issued to investors on Friday, Benzinga reports. The brokerage currently has a “hold” rating on the biotechnology company’s stock. Canaccord Genuity Group‘s price objective indicates a potential upside of 2.59% from the company’s current price.

Several other research firms have also recently commented on ASND. Jefferies Financial Group lowered their target price on shares of Ascendis Pharma A/S from $333.00 to $330.00 and set a “buy” rating for the company in a research note on Monday, August 31st. Wall Street Zen raised shares of Ascendis Pharma A/S from a “hold” rating to a “buy” rating in a research report on Sunday, November 8th. Stifel Nicolaus lowered their price objective on Ascendis Pharma A/S from $328.00 to $326.00 and set a “buy” rating for the company in a report on Monday, August 31st. Bank of America cut their target price on Ascendis Pharma A/S from $306.00 to $304.00 and set a “buy” rating on the stock in a research note on Monday, August 31st. Finally, Weiss Ratings restated a “hold (c)” rating on shares of Ascendis Pharma A/S in a research report on Tuesday, October 13th. Nineteen investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $306.55.

Ascendis Pharma A/S Stock Performance

Shares of ASND stock opened at $267.07 on Friday. The firm has a fifty day moving average price of $242.58 and a 200 day moving average price of $239.65. The company has a market cap of $16.66 billion, a P/E ratio of 20.72 and a beta of 0.40. Ascendis Pharma A/S has a 12 month low of $188.07 and a 12 month high of $282.15. The company has a current ratio of 2.99, a quick ratio of 2.32 and a debt-to-equity ratio of 0.27.

Ascendis Pharma A/S (NASDAQ:ASND) last issued its quarterly earnings data on Friday, August 14th. The biotechnology company reported $1.03 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.71 by ($0.68). Ascendis Pharma A/S had a return on equity of 32.54% and a net margin of 70.99%. The firm had revenue of $387.22 million for the quarter, compared to analysts’ expectations of $376.75 million. Sell-side analysts predict that Ascendis Pharma A/S will post 3.43 earnings per share for the current fiscal year.

Insider Activity at Ascendis Pharma A/S

In other news, SVP Mads Bodenhoff sold 3,000 shares of the company’s stock in a transaction on Tuesday, September 8th. The stock was sold at an average price of $270.19, for a total transaction of $810,570.00. Following the completion of the sale, the senior vice president directly owned 3,000 shares of the company’s stock, valued at $810,570. This represents a 50.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. 40.00% of the stock is currently owned by corporate insiders.

Institutional Trading of Ascendis Pharma A/S

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Allworth Financial LP boosted its position in shares of Ascendis Pharma A/S by 103.4% in the second quarter. Allworth Financial LP now owns 240 shares of the biotechnology company’s stock worth $64,000 after buying an additional 122 shares during the period. EverSource Wealth Advisors LLC lifted its position in Ascendis Pharma A/S by 34.0% in the 1st quarter. EverSource Wealth Advisors LLC now owns 272 shares of the biotechnology company’s stock worth $62,000 after buying an additional 69 shares in the last quarter. Fifth Third Bancorp lifted its position in Ascendis Pharma A/S by 48.4% in the 3rd quarter. Fifth Third Bancorp now owns 279 shares of the biotechnology company’s stock worth $64,000 after buying an additional 91 shares in the last quarter. Parallel Advisors LLC boosted its stake in shares of Ascendis Pharma A/S by 94.9% during the 1st quarter. Parallel Advisors LLC now owns 304 shares of the biotechnology company’s stock valued at $70,000 after buying an additional 148 shares during the period. Finally, IFP Advisors Inc boosted its stake in shares of Ascendis Pharma A/S by 3,491.7% during the 2nd quarter. IFP Advisors Inc now owns 431 shares of the biotechnology company’s stock valued at $115,000 after buying an additional 419 shares during the period.

Ascendis Pharma A/S News Roundup

Investors following ASND have been watching these news items:

• Positive Sentiment: Ascendis reported Q3 product revenue of €366 million, up 89% year over year, led by YORVIPATH at €291 million. The company also reported better-than-expected earnings and revenue, and said it expects at least €600 million in operating cash flow for the full year. Ascendis Pharma Reports Third Quarter 2026 Financial Results
• Neutral Sentiment: HC Wainwright lowered its price target from $344 to $335 but kept a Buy rating, indicating continued optimism while trimming its valuation view. HC Wainwright recommendations
• Neutral Sentiment: The company granted 28,030 employee warrants, which may have a modest dilutive effect. Ascendis Pharma Grants 28,030 Employee Warrants

About Ascendis Pharma A/S

Ascendis Pharma A/S is a biopharmaceutical company headquartered in Denmark that develops medicines for rare diseases, with a focus on endocrinology. Founded in 2006, the company uses its TransCon technology platform to design therapies intended to provide sustained delivery of medicines. Its commercial products include SKYTROFA (lonapegsomatropin), a once-weekly growth hormone treatment for children with growth hormone deficiency, and YORVIPATH (palopegteriparatide), a treatment for adults with hypoparathyroidism.